ArticleEmerging infectious diseases2023
Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
Article in Emerging infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Catalytic and Antitubercular Activities of Multifunctional Copper(II)-Schiff Base Complexes: Insights into Structure, Theoretical Calculations, and Physicochemical Behavior.Inorganic chemistry · 2026Article
- Rising bedaquiline resistance: exploring potential causes and next steps.The European respiratory journal · 2026Article
- Socio-ecological vulnerability subgroups predict adherence and treatment outcomes in multidrug-resistant tuberculosis and HIV: a latent class analysis.BMC infectious diseases · 2026Article
- Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.The Journal of clinical investigation · 2026Article
- Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022-2024.Open forum infectious diseases · 2026Article
- Article
- Glucose driven bacterial persistence in extensively drug-resistant tuberculosis with diabetes.Frontiers in public health · 2026Article
- Identification of novelFuture medicinal chemistry · 2025Article
- Immunomodulatory Nanoparticles Induce Autophagy in Macrophages and ReduceACS infectious diseases · 2025Article
- In Vitro Activity of the Triazinyl Diazepine Compound FTSD2 Against Drug-ResistantPharmaceuticals (Basel, Switzerland) · 2025Article
- Unveiling the Antimycobacterial Potential of Novel 4-Alkoxyquinolines: Insights into Selectivity, Mechanism of Action, andJournal of medicinal chemistry · 2024Article
- Frameshift mutations in theAntimicrobial agents and chemotherapy · 2024Article
- Strategies to Enhance Diagnostic Capabilities for the New Drug-Resistant Tuberculosis (DR-TB) Drugs.Pathogens (Basel, Switzerland) · 2024Review
- Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia.Emerging infectious diseases · 2024Article
- Emerging Extracellular Molecular Targets for Innovative Pharmacological Approaches to Resistant Mtb Infection.Biomolecules · 2023Review
- Delamanid and bedaquiline resistance patterns inNew microbes and new infectionsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
New classes of antitubercular drugs, diarylquinolines and nitroimidazoles, have been associated with improved outcomes in the treatment of drug-resistant tuberculosis, but that success is threatened by emerging drug resistance. We report a case of bedaquiline and delamanid resistance in a 55-year-old woman in South Africa with extensively drug-resistant tuberculosis and known HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.